ArticleEuropean journal of nuclear medicine and molecular imaging2026
Amygdalar metabolic activity associated with cerebrovascular events and carotid-vertebral artery stenosis in takayasu arteritis.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the association of amygdalar activity with disease activity, inflammatory markers, cerebrovascular events, and structural vascular injury in patients with Takayasu arteritis (TAK).
methodsA total of 303 TAK patients underwent 18F-fluorodexoyglucose positron emission tomography/computed tomography (¹⁸F-PET/CT). Amygdalar, bone marrow, and vessel wall SUV were quantified. Clinical, laboratory, and imaging data were collected. The median follow-up duration was 27 months, during which adverse events were recorded.
resultsNo significant association was found between amygdalar SUV and cerebrovascular events in the overall cohort. However, among treatment-naïve patients, those with cerebrovascular events had significantly lower amygdalar SUVmax (9.3±2.0 v.s. 10.3±2.0, p=0.011) and SUVmean (6.6±1.2 v.s. 7.4±1.5, p=0.003) than event-free patients. The low SUV group had a higher proportion of cerebrovascular events (24.3% vs. 15.9%, P=0.045), along with elevated IgG and IgA levels and decreased lymphocyte counts. Amygdalar SUVmax was an independent protective factor against combined carotid and vertebral artery stenosis (OR=0.876, P=0.032). During follow-up, the event group had significantly lower amygdalar SUVmax than the new-onset symptom group (8.2±2.6 v.s. 10.4±1.8, P=0.030).
conclusionLow amygdalar metabolic activity in TAK is associated with adverse vascular outcomes and serves as an independent protective factor against combined carotid-vertebral artery stenosis, suggesting its potential as a novel imaging biomarker.
Indexed as
Identifiers
42560520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.